Carlsbad, CA, United States
Carlsbad, CA, United States

Time filter

Source Type

News Article | November 10, 2016
Site: www.prweb.com

Skin Care Institute is proud to introduce Volbella®, the innovative new lip filler treatment that can plump thin lips and smooth facial lines for a refreshed appearance. In adding Volbella to their extensive list of services, Skin Care Institute team have placed themselves in a class of their own among the top injectable destinations in Oklahoma. Ideal candidates for FDA-approved Volbella are those who feel that their lips have thinned out with age, or those who have always had thin lips and desire a smoother and more plump appearance. While results are not permanent, they are long-lasting, and treatments take no longer than thirty minutes. The process is as simple as a few strategic injections made in the area around the mouth. Tulsa Volbella is formulated with a smooth gel that helps to maintain the natural feel and smooth consistency of the lips. It also contains lidocaine, a light anesthetic that allows Skin Care Institute’s expert staff to provide maximum patient comfort throughout the treatment. With Volbella treatments, there are no implants, no surgery, and no downtime. For even greater results, Volbella in Tulsa can be combined with Botox® or other dermal filler injections. Recently voted Best Medical Spa in Oklahoma Magazine’s 2016 “Best of the Best” awards, Skin Care Institute prides themselves on administering only the latest and most advanced skin care and facial rejuvenation treatments. Volbella is one of many cutting-edge options available at their office in Tulsa, and they plan to continue to provide top-level care for years to come. Skin Care Institute’s mission is to provide both men and women with the best in skin care and wellness. Dermatologist Jeff Alexander, MD, is always seeking the newest, safest and most effective technology for skin rejuvenation and anti-aging. A balanced blend of science and aesthetics is the foundation for the services provided by Skin Care Institute Medical & Wellness Spa, established in 1999. In 2012, Skin Care Institute added a "wellness" component to their medical spa. Skin Care Institute’s licensed professionals provide the finest in treatments and products in the relaxing and soothing atmosphere of a modern spa setting. With this combination, Skin Care Institute has become Oklahoma’s premier medical spa, offering treatments like Vectus laser hair removal, CoolSculpting® Botox®, Juvéderm®, Restylane®, Voluma XC™, Ultherapy®, Clear + Brilliant™, IPL Photo Facials, chemical peels and more. Skin Care Institute Medical & Wellness Spa is located in the Kelly Medical Building at 6565 South Yale Avenue, Suite 110 in Tulsa Oklahoma. Jeff Alexander, M.D., is owner and medical director of Skin Care Institute, L.L.C., Medical and Wellness Spa in Tulsa, Oklahoma. He is certified by the American Board of Dermatology and has over 30 years of experience in skin care. Dr. Alexander is a graduate of the University of Nebraska Medical School and the University of Oklahoma Dermatology Program. He has served as president of the Oklahoma Dermatological Society and the Tulsa Dermatological Society. Dr. Alexander is currently the chairman of the Department of Dermatology at St. Francis Hospital in Tulsa. He has served on the speaker’s bureau for GlaxoSmithKline, SkinCeuticals®, Novartis Pharmaceuticals and SkinMedica®. He is a Luminary for Inmode Laser Technologies. He has also served as assistant clinical professor and dermatology instructor for medical students and residents at the University of Oklahoma. In 1999, Dr. Alexander opened the first medical spa in Oklahoma, and one of the first in the Midwest, Skin Care Institute. In January 2012, Dr. Alexander expanded to include wellness services. By combining cutting edge laser technology with aesthetic, medical and wellness procedures, he paved the way for others in the industry. As medical director of Skin Care Institute, Dr. Alexander introduced laser hair removal, intense pulsed light FotoFacial™ rejuvenation, CoolSculpting®, Fraxel, Ultherapy® and Inmode Aesthetic Solutions to Oklahoma. He was awarded the prestigious honor of being one of the top two in North America for “Best Skin Tightening and Overall Results” by Reliant Technologies, manufacturer of the Fraxel repair™ laser. Oklahoma Magazine readers consistently vote him “Top Doctor” in Dermatology. His medical spa is repeatedly included in Oklahoma Magazine’s “Best of the Best” and Tulsa People Magazine’s “A-List.”


News Article | December 15, 2016
Site: www.prweb.com

Skin Care Institute, led by Dr. Jeff Alexander, always strives to provide their patients with exceptional results through only the safest and most advanced technology. With this goal in mind, they have become one of the first practices in the Tulsa area to offer the new 3-in-1 CoolAdvantage™ applicator for the CoolSculpting non-invasive fat removal system. These FDA-approved applicators enhance the efficiency of the treatment for an improved overall patient experience. By improving the design to increase direct tissue contact, the CoolAdvantage applicator cuts treatment time almost in half, for a faster and more comfortable treatment. This allows patients to spend less time sitting around and more time enjoying their slimmed down appearance. Using controlled cooling technology, CoolSculpting safely and effectively freezes fat cells under the skin. In the weeks and months that follow the treatment, the targeted cells are eliminated from the body through the lymphatic system. The treatment is completely non-invasive and requires no downtime, so patients can immediately resume their regular daily activites. With the addition of these applicators, Skin Care Institute continues to distinguish themselves as a local authority in body sculpting treatments. Beyond CoolSculpting, Dr. Alexander and his team also offer a full service spa and wellness center, and have expertise in a variety of other cosmetic treatments, including laser hair removal, Botox®, dermal fillers, and skin rejuvenation. Skin Care Institute’s mission is to provide both men and women with the best in skin care and wellness. Dermatologist Jeff Alexander, MD, is always seeking the newest, safest and most effective technology for skin rejuvenation and anti-aging. A balanced blend of science and aesthetics is the foundation for the services provided by Skin Care Institute Medical & Wellness Spa, established in 1999. In 2012, Skin Care Institute added a "wellness" component to their medical spa. Skin Care Institute’s licensed professionals provide the finest in treatments and products in the relaxing and soothing atmosphere of a modern spa setting. With this combination, Skin Care Institute has become Oklahoma’s premier medical spa, offering treatments like Vectus laser hair removal, CoolSculpting® Botox®, Juvéderm®, Restylane®, Voluma XC™, Ultherapy®, Clear + Brilliant™, HydraFacial MD®, IPL Photo Facials, chemical peels and more. Skin Care Institute Medical & Wellness Spa is located in the Kelly Medical Building at 6565 South Yale Avenue, Suite 110 in Tulsa Oklahoma. About Dr. Jeff Alexander, Medical Director of Skin Care Institute Jeff Alexander, M.D., is owner and medical director of Skin Care Institute, L.L.C., Medical and Wellness Spa in Tulsa, Oklahoma. He is certified by the American Board of Dermatology and has over 30 years of experience in skin care. Dr. Alexander is a graduate of the University of Nebraska Medical School and the University of Oklahoma Dermatology Program. He has served as president of the Oklahoma Dermatological Society and the Tulsa Dermatological Society. Dr. Alexander is currently the chairman of the Department of Dermatology at St. Francis Hospital in Tulsa. He has served on the speaker’s bureau for GlaxoSmithKline, SkinCeuticals®, Novartis Pharmaceuticals and SkinMedica®. He is a Luminary for Inmode Laser Technologies. He has also served as assistant clinical professor and dermatology instructor for medical students and residents at the University of Oklahoma. In 1999, Dr. Alexander opened the first medical spa in Oklahoma, and one of the first in the Midwest, Skin Care Institute. In January 2012, Dr. Alexander expanded to include wellness services. By combining cutting edge laser technology with aesthetic, medical and wellness procedures, he paved the way for others in the industry. As medical director of Skin Care Institute, Dr. Alexander introduced laser hair removal, intense pulsed light FotoFacial™ rejuvenation, CoolSculpting®, Fraxel, Ultherapy® and Inmode Aesthetic Solutions to Oklahoma. He was awarded the prestigious honor of being one of the top two in North America for “Best Skin Tightening and Overall Results” by Reliant Technologies, manufacturer of the Fraxel repair™ laser. Oklahoma Magazine readers consistently vote him “Top Doctor” in Dermatology. His medical spa is repeatedly included in Oklahoma Magazine’s “Best of the Best” and Tulsa People Magazine’s “A-List.”


Patent
Arch Personal Care Products L.P. and SkinMedica | Date: 2011-11-11

Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition.


News Article | February 15, 2017
Site: www.prweb.com

Sara Shikhman, Practice Manager of Juvly Aesthetics in Ohio and New York City was selected as one of few aesthetic professionals in the country to sit on the 2017 National Advisory Board for Allergan’s Brilliant Distinctions consumer loyalty program. As Practice Manager of Juvly Aesthetics, in just 2 years Sara helped propel the clinic from a small start-up to number 78 in the country based on sales volume of Allergan cosmetic products, while earning 5 star ratings from Juvly clients. Juvly’s motto is fair prices and fantastic results, and all prices are posted online at http://www.juvly.com/pricing. "The invitation by Allergan to serve on this Advisory Board is not only an honor but also a great example of Allergan's commitment to innovation and research," she said. "I am hopeful that our Board's contributions will enrich the Brilliant Distinctions Program so that Botox® clients all over the United States will realize even more savings. The Advisory Board is meeting in February 2017 in Dana Point, CA. About Juvly Aesthetics Founded by Dr. Justin Harper in 2014, Juvly Aesthetics has grown to one of the largest and most highly acclaimed aesthetic practices in the country. Juvly has offices in Columbus, OH, New York, NY, Cincinnati, OH and Polaris, OH. The clinic specializes in non-surgical aesthetic procedures including Allergan’s portfolio of injectable products. In addition, Juvly offers anti-aging laser procedures, non-surgical fat reduction with Coolsculpting and Cellfina cellulite reduction treatments. About Allergan Allergan is the global multi-specialty health care corporation that produces cosmetic products such as Botox®, Juvederm®, Juvederm Voluma®, Kybella®, Juvederm Volbella®, Latisse® and SkinMedica®. Brilliant Distinctions® is Allergan's customer loyalty program.


BACKGROUND and Skin lightening preparations are used by people all over the world for a diverse range of dermatologic indications. Hydroquinone (HQ) is the gold standard and remains the only prescription product available in the United States for the treatment of generalized facial hyperpigmentation. Irritation and the risk of exogenous ochronosis are the main adverse effects for concern. Therefore, there has been a constant search for new treatment alternatives. Understanding the molecular mechanisms involved in pigmentation has resulted in the development of a series of formulations that utilize a multimodal treatment approach. These proprietary formulas combine skin lightening agents that act via different mechanisms of action. The actives included 4-ethoxybenzaldehyde (anti-inflammatory and prostaglandin E2 suppressor), licorice extract (tyrosinase inhibitor), tetrahexyldecyl ascorbate (antioxidant), niacinamide (melanosome transport inhibitor), ethyl linoleate (tyrosinase inhibitor; enhances turnover of epidermis), hexylresorcinol (tyrosinase inhibitor), and retinol (tyrosinase transcription inhibitor; enhances turnover of epidermis). Select formulations were tested in several studies using the MelanoDerm™ Skin Model (MatTek Corporation, Ashland, MA) to assess the ability of the product to reduce melanin production and distribution. A single-center, double-blind comparison clinical study of 18 subjects was conducted to evaluate the efficacy of the product in reducing ultraviolet-induced hyperpigmentation. Test sites were irradiated with 1.0, 1.5, 2.0, and 2.5 minimal erythema doses. After 5 days, to allow for pigmentation development, the product or 4% HQ cream was applied to the respective test sites, once daily for 4 weeks. Chroma Meter measurements (L* brightness) and standardized digital photographs were taken of the test sites twice a week. The test product resulted in greater reduction in melanin as measured by melanin content and histological staining compared with the positive control in the MelanoDerm Skin Model. The product also demonstrated statistically significant reductions in pigmentation compared with baseline (all P ≤.0001) at the end of the clinical study, and produced greater increases in L*, compared with 4% HQ. Results from these studies indicate that a product designed to affect multiple pathways of melanogenesis and melanin distribution may provide an additional treatment option beyond HQ for hyperpigmentation.


Makino E.T.,SkinMedica
Journal of drugs in dermatology : JDD | Year: 2013

There are numerous common skin disorders involving hyperpigmentation, including solar lentigines, postinflammatory hyperpigmentation, melasma, freckles, and dyschromia from photoaging. While these conditions are of an aesthetic nature, there is great interest in newer, safer, and more effective treatment modalities. Topical hydroquinone (HQ) has been the gold standard of skin lighteners for many years. However, regulatory authorities around the world are now questioning its safety. A randomized, double-blind, half-face study was conducted in females with moderate to severe facial hyperpigmentation to assess the efficacy and tolerability of 3 new skin brightener formulations containing SMA-432, a prostaglandin E2 inhibitor, compared with 4% HQ. Each subject was assigned 2 of the 4 test materials and was instructed to apply the product on the assigned side of the face twice daily for 12 weeks. Evaluation visits were conducted at baseline and at 4, 8, and 12 weeks. At each visit, subjects were evaluated by a blinded investigator for clinical efficacy and tolerability using grading scales. Standardized digital photography and Chroma Meter assessments were also taken. Self-assessment questionnaires were completed at weeks 4, 8, and 12. Sixty-eight Caucasian subjects (136 half faces) completed the study. All test materials significantly reduced Overall Hyperpigmentation and improved the Investigator's Global Hyperpigmentation Improvement rating at weeks 4, 8, and 12 compared with baseline. SMA-432 exhibited a dose-dependent improvement in hyperpigmentation. There were no major tolerability issues with any of the test materials. Self-assessments were generally favorable for all test materials. At the completion of the trial, subjects rated one of the tested multimodality brightener compositions as the most favorable product and 4% HQ as the least favorable. This study demonstrated that the new non-HQ-containing skin brightener formulations were as effective and equally well tolerated as the gold standard, 4% HQ, in females with facial hyperpigmentation.


Patent
SkinMedica | Date: 2012-06-25

A method for the modification of melanin distribution, and the composition thereof to modify melanin distribution are disclosed. A method for the reduction of melanin distribution, and the composition thereof to reduce melanin distribution are disclosed. A representative composition comprises 4-ethoxybenzaldehyde and one or more additional active agents as well as a pharmaceutically acceptable carrier or excipient. Carriers and excipients may be formulated for topical administration. Compositions may also be formulated for transdermal administration. The compositions may be used for the prevention and treatment of pigmentation disorders, by way of non-limited example, post-inflammatory hyperpigmentation and others. The compositions may be used for lightening skin.


Patent
SkinMedica | Date: 2012-01-06

A method for the modification of melanin distribution, and the composition thereof to modify melanin distribution are disclosed. A method for the reduction of melanin distribution, and the composition thereof to reduce melanin distribution are disclosed. A representative composition comprises 4-ethoxybenzaldehyde and one or more additional active agents as well as a pharmaceutically acceptable carrier or excipient. Carriers and excipients may be formulated for topical administration. Compositions may also be formulated for transdermal administration. The compositions may be used for the prevention and treatment of pigmentation disorders, by way of non-limited example, post-inflammatory hyperpigmentation and others. The compositions may be used for lightening skin.


Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.


Patent
SkinMedica | Date: 2011-09-23

The present invention provides a skin peel composition including a plurality of substances, such as lactic acid, salicylic acid, and resorcinol and, additionally a post-inflammatory hyper pigmentation reducing substance such as a retinol (vitamin A) or retinol derivative. Skin is first prepared using an alcohol preparation followed by a combinations of acids and, lastly, a retinol or retinol derivatives. Other agents such as ascorbic acid (vitamin C) and vitamin E can be added as needed. Application of the skin peel composition may be either topically in the form of a cream or gel, and may further be injected subcutaneously into the skin to achieve deeper penetration of the composition within the skin layers of the area to be treated.

Loading SkinMedica collaborators
Loading SkinMedica collaborators